Bayer HealthCare recently announced it will test the efficacy and safety of the drug Riociguat in patients with symptomatic pulmonary hypertension (PH) associated with idiopathic interstitial pneumonias (IIP). The study will take place at more than 50 sites in 11 countries and will include about 120 patients. Designed…

Researchers from the University of California, San Diego, presented a new study at the 2014 American Thoracic Society International Conference revealing the effects of pulmonary thromboendarterectomy (PTE) in patients with chronic pulmonary thromboembolic disease, suggesting a positive effect in patients’ conditions after the procedure. Daniel Crouch, MD, pulmonary and critical fellow…

According to recent data, there is a direct correlation between pulmonary emboli that result in the onset of pulmonary hypertension (PH) — an under recognized condition that researchers and medical practitioners alike hope to address in the PH patient population. Pulmonary embolism is the clinical condition marked by a…

Results released Monday, May 5th from Canada’s Pulmonary Hypertension Association (PHA) Patient and Caregiver Survey revealed that those in Canada diagnosed with pulmonary hypertension (PH) are experiencing serious financial, social, and physical burdens as a result of being diagnosed with disease. Chief among the difficulties experienced among the PH…

Among the fives types of PH, Pulmonary Arterial Hypertension (PAH) is recognized as a serious unmet medical need in terms of viable treatments, due to the progressive and life-threatening characteristics of the disease.  PAH patients experience symptoms where blood pressure in the pulmonary arteries is significantly heightened due to vasoconstriction, frequently…

A few weeks ago, a close friend who also manages a rare disease asked for my thoughts on artificial intelligence (AI) in healthcare. She sounded anxious — AI was suddenly appearing in her medical appointments, and she wasn’t sure what to make of it. This issue has actually been on…

A clinical trial testing mosliciguat, an inhaled therapy for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD), has wrapped up enrollment, and in less than one year since treating the first participant. That announcement was made by Pulmovant, the company developing the drug…

Artificial intelligence (AI) tools developed by Etiometry may help to predict, among other outcomes, the length of a patient’s hospital stay following surgery among people with chronic thromboembolic pulmonary hypertension (CTEPH). As such, these tools could potentially be used to improve patient care, and better monitor post-surgery recovery,…

Levels of the enzyme PRDX2 increase as a protective response in chronic thromboembolic pulmonary hypertension (CTEPH) and help reduce damage to blood vessels in the lungs, a new study in laboratory rats has found. The researchers discovered that the antioxidant enzyme worked to reduce vessel damage by limiting inflammation,…

People with chronic thromboembolic pulmonary hypertension (CTEPH) continue to experience significant symptoms that interfere with daily life, even when receiving treatment, according to a real-world U.S. study. The study also found that people treated at Pulmonary Hypertension Association (PHA)-accredited centers tended to have more severe…

People with chronic thromboembolic pulmonary hypertension (CTEPH) who have a high pulmonary arterial wedge pressure (PAWP) — a measure of pressure in the heart’s left atrium, which receives blood from the lungs…

Two proteins associated with the aggregation and activation of platelets may serve as biomarkers of chronic thromboembolic pulmonary hypertension (CTEPH) severity and progression, according to a study conducted in China. The proteins, PAD4 and NOX2, were elevated in platelets of people with CTEPH compared with healthy individuals, suggesting they may…